Source: Υπουργείο Υγείας (CY) Revision Year: 2017 Publisher: Medochemie Ltd, 1-10 Constantinoupoleos Street, 3011, Limassol, Cyprus
Pharmacotherapeutic group: Blood glucose lowering drugs, excl. insulins, Sulphonylureas
ATC code: A10BB01
The pharmacodynamic effect of glibenclamide is to lower blood glucose levels.
Mechanisms proposed for this effect include:
Plasma glucose levels affect the insulin-releasing response to glibenclamide (a high glucose levels increases the response). The minimum active concentrations for effect are considered to be 30-50nanograms/ml glibenclamide.
Investigations of the relationship between insulin, glucose levels and glibenclamide in the hypoglycaemic effect continue.
A sulphonylurea hypoglycaemic agent rapidly absorbed and inducing its effect within 3 hours with a duration of up to 15 hours although the T1/2 of drug is 5 to 10 hours.
The drug is metabolised extensively in the liver and excreted via bile and urine. It is strongly protein-bound.
None of clinical relevance.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
